

PRESS RELEASE

Stockholm November 24, 2022

ADDvise receives order worth USD 1.7 million

ADDvise Group AB's subsidiary MRC Systems FZE has received an order from BioGeneric Pharma, a leading factory in biotechnology based in Cairo, Egypt. The order is worth approximately USD 1.7 million. The order is an add-on-project in the ongoing project between the parties regarding design, supply, and commissioning of clean room environment to be used for production of mRNA-vaccine. BioGeneric Pharma has been selected by the World Health Organization (WHO) to be the first technology transfer recipient of mRNA-vaccine hub in Egypt for distribution in Africa. Delivery of the order is planned to take place during Q2 2023. We are happy to contribute with our knowledge and expertise in the clean room space.

For further information, please contact:

Rikard Akhtarzand, CEO
+46 765-25 90 71
rikard.akhtarzand@addvisigroup.se

Important information:

This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on November 24, 2022, at 16:00 CET.

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group's shares are listed on Nasdaq First North Premier and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisigroup.com.